Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain.
(Q44460129)
scientific article published on 31 May 2003
scientific article published on 31 May 2003
Language: